Navigation Links
CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development

INDIANAPOLIS, Oct. 28 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced today that it has appointed Linda Hogan as Vice President of Business Development. In this position, Hogan will apply more than 25 years of experience in the pharmaceutical and biopharmaceutical industries to drive CoLucid's business development strategies. She will lead partnering initiatives and transactions for the company's rapidly advancing pipeline of compounds for the treatment of central nervous system (CNS) disorders.

Hogan continues to serve as an Executive in Residence at Care Capital, LLC where she assists with the sourcing and evaluation of potential investment opportunities, including the formation of new companies, and provides business development support to portfolio companies. She previously served as Vice President of Business Development with Clearview Projects, Inc. and was Vice President of Business Development at Aventis. Hogan received an MBA from Rockhurst College and an MS in Hospital Pharmacy at the University of Kansas School of Pharmacy.

The company also announced that Nadia Rupniak has been promoted to Vice President of Research and Development, where she will lead the advancement of the company's late-stage and preclinical therapeutic candidates.

Rupniak has more than 20 years of experience in the pharmaceutical industry, including more than two years with CoLucid. She previously held positions at Merck and at Dynogen Pharmaceuticals, Inc, where she served as the head of technology transfer.

"We are building and adding to our team to support the continued advancement of COL-144 for the acute treatment of migraine and our other drug candidates," said James White, CEO of CoLucid Pharmaceuticals. "We congratulate Nadia Rupniak on her promotion, which reflects the important contributions she has made in helping CoLucid meet our clinical and research objectives, and we are very pleased to bring Linda Hogan on board. Linda is a skilled and accomplished business development professional who is able to draw on a breadth of experience at Care Capital and Clearview to help advance CoLucid's partnering initiatives."

"I look forward to working with CoLucid to help identify key business targets and to set the future direction of CoLucid's product development and partnering strategies," said Hogan. "I am very excited about the market and partnering potential for the company's pipeline of innovative CNS product candidates."

CoLucid Pharmaceuticals recently announced positive results from its Phase II clinical study of its lead compound, COL-144, in the treatment of acute migraine. Findings from the study demonstrated that COL-144 is effective in relieving migraine headaches and is well tolerated.

COL-144 is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapy. COL-144 selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway. In addition to COL-144, CoLucid's pipeline includes a conjugated stigmine platform that has generated a series of preclinical candidates for the treatment of sleep/wake disorders, chronic pain, Alzheimer's disease and psychiatric disorders. COL-204, the lead compound in the conjugated stigmine program, is expected to enter clinical development in 2009 for wake promotion.

About CoLucid Pharmaceuticals, Inc.

CoLucid Pharmaceuticals was founded in December 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatment for central nervous system (CNS) disorders. The company's pipeline includes COL-144, a novel treatment for migraine headache, and a conjugated stigmine platform that has generated a series of preclinical candidates for the treatment of sleep/wake disorders, chronic pain, Alzheimer's disease and psychiatric disorders. For more information, please visit CoLucid at

SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound
2. Anadys Pharmaceuticals to Present at Bio Investor Forum
3. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
4. Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008
5. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
6. Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
7. ISTA Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2008
8. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
9. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
10. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
11. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... Dr. Thomas Dunlap and Dr. Patrick Coleman ... with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , ... in similar ways and require time-critical intervention to avoid large area heart damage and ...
(Date:11/27/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class ... (Long Term Support) into its Q-Suite 5.10 product line. , Making the change ... version of Asterisk that will receive not only security fixes, but feature and ...
(Date:11/26/2015)... , ... November 26, 2015 , ... Inevitably when people ... customers choose to buy during the Black Friday and Cyber Monday massage ... need to search the Internet high and low to find the best massage chair ...
(Date:11/26/2015)... ... 26, 2015 , ... Somu Sivaramakrishnan announced today that he ... now offers travelers, value and care based Travel Services, including exclusive pricing on ... as, cabin upgrades and special amenities such as, shore excursions, discounted fares, travel ...
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical laboratories and in the ... healthcare staffing agency Aureus Medical Group . These fields, as well ... those searching for healthcare jobs through the company’s website, , The ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... , November 26, 2015 ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... has found that immunotherapy can be efficiently combined ...
(Date:11/26/2015)... 2015 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ... demands kidney transplantation is expected to boost the market growth, ... organ transplantation. --> 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ...
Breaking Medicine Technology: